Shenzhen Beike Biotechnology Co., Ltd. is a high-tech enterprise specializing in the clinical transformation and technical services of biotherapy technology in strategic emerging industries, and its immunotherapy technology and products are well-known in the industry
Founded in July 2005, Shenzhen Beike Biotechnology Co., Ltd. (hereinafter referred to as Beike Biotechnology) is an earliest high-tech enterprise specializing in clinical transformation and technical services of biotherapeutic technology in strategic emerging industries in our country. The company has more than 400 employees, of which more than 35% are technical R&D personnel, and has a professional technical R&D team led by many experts and scholars at home and abroad with outstanding achievements in the field of cells.
Multiple subsidiaries:Jiangsu Beike, Shanghai Beike, Anhui Beike, Liaoning Beike, Henan Beike, Guizhou Beike, Jiangxi Beike, Hebei Beike, Beike International (Hong Kong), Beike International (India), etc.
Global Clinical Research Technical Support Network:Beike Biotech has carried out cell technology-related cooperation with more than 400 scientific research and medical institutions at home and abroad, and has provided personalized cell preparation technology services for cell therapy for more than 80,000 patients with refractory diseases, including patients from more than 70 countries such as the United States, Canada, the United Kingdom, and Japan, and the remarkable results have been highly recognized by the international academic community.
Advanced immune cell therapy technology:Through strategic licensing, mergers and acquisitions and independent research and development, Beike occupies an important strategic position in the field of immunotherapy. Beike has a variety of international advanced immunotherapy technologies and products. ALT803 is considered by the NCI to be a more promising interleukin drug for curing cancer. Bispecific antibodies, MCAR-T, MCAR-NK cell therapy developed under the R&D platform of major histocompatibility complex antigen recognition receptors have more significant therapeutic advantages in diseases such as malignant hematological diseases, solid tumors, and viral infections than the current conventional CAR-T, TCR-T, and bispecific antibodies.
National Network of Integrated Cell Banks and Regional Cell Preparation Centers:By "laying" a "cell therapy highway network" that can not only meet the timeliness of clinical needs, but also take into account the scale of production, it provides an innovative public technology platform and infrastructure for the clinical transformation of cell therapy technology. It has been completed and ordered in Shenzhen, Jiangsu, Guizhou, Jiangxi, Guangxi and XinjiangThe remarkable achievements provide an innovative path for the development model of our country's cell therapy industry.
